Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Context. —Angiotensin-converting enzyme (ACE) inhibitors are associated with an increased risk of angioedema, but the risk of recurrent angioedema if treatment is continued is not known. Objective. —To test the hypothesis that the association between ACE inhibitor use and angioedema may not be recognized and to determine characteristics of angioedema associated with continued use of ACE inhibitors. Design. —Retrospective cohort study. Setting. —Tennessee Medicaid program. Patients. —Medicaid enrollees aged 15 years or older who used an ACE inhibitor and had a first documented episode of angioedema between 1986 and 1992 were followed up for recurrent episodes through June 1993. Measurements and Main Results. —We previously identified 82 patients with a first confirmed diagnosis of angioedema during 51 752 person-years of ACE inhibitor use in this population (1.6 per 1000 person-years). Among these 82 patients, there were 16 outpatient recurrences of angioedema among 13 patients during 189 patient-years of follow-up (8.5 per 100 patient-years). The rate of angioedema was much higher in users of ACE inhibitors with continued exposure (18.7 per 100 patient-years) than in those whose use of the drug was discontinued (1.8 per 100 patient-years) (P=.001). Review of the medical records for patients taking ACE inhibitors who had recurrent angioedema revealed that physicians attributed angioedema to a number of causes not related to ACE inhibitor use, even after multiple recurrences. Conclusion. —Continuing use of ACE inhibitors in spite of angioedema results in a markedly increased rate of angioedema recurrence with serious morbidity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Israili, Z. H., & Hall, W. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-234 · Cited by 910
Brown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90161-7 · Cited by 313
Self-citation
Cited by
Cicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J. A., Bork, K., Caballero, T., Farkas, H., Grumach, A., Kaplan, A. P., et al. (2014) · Allergy · doi:10.1111/all.12380 · Cited by 666
Sicherer, S. H., & Sampson, H. A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.05.048 · Cited by 647
Angiotensin-Converting Enzyme Inhibitors in Hypertension
Messerli, F. H., Bangalore, S., Bavishi, C., & Rimoldi, S. F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.058 · Cited by 349
Kaplan, A. P., & Greaves, M. W. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.09.032 · Cited by 313
The genetic basis of variability in drug responses
Roden, D. M., & George Jr, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 292
Metadata
- Authors
- Brown, N. J.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1997-07-16
- Volume
- 278
- Issue
- 3
- Pages
- 232
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4232173207
- Cited by
- 122
- References
- 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema. https://app.cochat.ai/papers/10.1001/jama.1997.03550030072037
- The paper
- Brown, N. J. (1997). Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1997.03550030072037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.